Goeril Karlsson
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.
Journal: European journal of neurology
Published: September 10, 2025
Personalized Treatment Response in Progressive MS: Can the Patient's Profile Influence the Outcome?
Journal: Brain and behavior
Published: September 06, 2024
Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: September 11, 2023
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
Journal: Neurology and therapy
Published: April 04, 2023
Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
Journal: Neurology and therapy
Published: February 10, 2023
MRI versus relapse: optimal activity monitoring for management of progressive multiple sclerosis.
Journal: Brain communications
Published: February 08, 2023
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: April 05, 2022
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: March 09, 2022
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Journal: Journal of neurology
Published: August 24, 2021
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 18, 2020
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
Journal: Neurology
Published: October 28, 2019
Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: January 19, 2018
Last Updated: 09/26/2026